PTPRC and osteosarcoma: Similarly, PBMC samples from non-metastatic osteosarcoma showed higher percentages of CD45+ cells (30.34% vs. 19.24%), CD3+ cells (5.662% vs. 2.057%), macrophage (10.19% vs. 6.849%), and M1 macrophage (8.378% vs. 5.620%) than those from metastatic osteosarcoma.